Scientists discover mutation that causes PARP inhibitor resistance

Scientists have identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors. This major discovery could help doctors to tailor treatment at the earliest opportunity by predicting which patients are likely to develop resistance to PARP inhibitors treatment.
“The evolution of cancers into drug resistant forms is a major challenge we face in getting cancer treatments to work,” noted study leader Professor Chris Lord, Professor of Cancer Genomics at The ICR. “We hope our research will help doctors use the best drug right from the outset, respond quickly to early signs of resistance, and work out the best ways to combine treatments to overcome drug resistance.”